Summary
OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant from the Cancer Prevention and Research Institute of Texas(CPRIT). The funding will be used to support the company’s continued development of a new class of pH-activated compounds that digitize and exploit the variability of pH in disease indications. The company is also pleased to announce the appointment of five established industry leaders to its inaugural Board of Directors.